Campbell, California–based Imperative Care designed Zoom for fast and effective clot removal from access through reperfusion. It treats patients with acute ischemic stroke, enabling smooth tracking through challenging vasculature.
The study examines treatments in patients suffering from acute ischemic stroke due to a primary occlusion of the M2 segment of the middle cerebral artery within eight hours of symptom onset. Investigators plan to enroll patients in a 1:1 randomization. They’ll measure clinical outcomes using the 90-day modified Rankin Scale (mRS) score. This reflects a patient’s level of disability post-stroke.
Patients randomized to the Zoom arm receive treatment with dual aspiration using the continuous dual aspiration technique (CDAT). This technique applies continuous vacuum on two Zoom catheters simultaneously, incorporating Imperative Care’s DuoPort technology.
Dr. Adam Arthur serves as the study’s principal investigator. Arthur said this marks the first trial to look at an aspiration approach specifically for M2 occlusions. It could help clinicians “better understand the potential impact of aspiration thrombectomy on these patients.”
“We believe it is our responsibility to support the launch of independent randomized controlled trials that rigorously evaluate treatment approaches with the ultimate goal of improving patient outcomes,” said Fred Khosravi, chair and CEO of Imperative Care. “This investment reflects our deep commitment to clinical evidence and innovation. We are grateful to the leading clinicians participating in this trial, and we look forward to the impact these findings will ultimately have on patients.”
